ABC Arbitrage SA Sells 467,275 Shares of Smith & Nephew SNATS, Inc. $SNN

ABC Arbitrage SA decreased its position in shares of Smith & Nephew SNATS, Inc. (NYSE:SNN) by 61.6% in the 1st quarter, according to its most recent 13F filing with the SEC. The firm owned 290,681 shares of the medical equipment provider’s stock after selling 467,275 shares during the quarter. Smith & Nephew SNATS makes up 1.2% of ABC Arbitrage SA’s investment portfolio, making the stock its 18th largest position. ABC Arbitrage SA’s holdings in Smith & Nephew SNATS were worth $9,238,000 at the end of the most recent quarter.

Other large investors also recently added to or reduced their stakes in the company. Garner Asset Management Corp bought a new stake in Smith & Nephew SNATS in the 4th quarter valued at about $27,000. Arax Advisory Partners boosted its holdings in shares of Smith & Nephew SNATS by 142.6% in the fourth quarter. Arax Advisory Partners now owns 968 shares of the medical equipment provider’s stock worth $32,000 after acquiring an additional 569 shares during the period. Advisors Asset Management Inc. bought a new stake in shares of Smith & Nephew SNATS during the fourth quarter valued at about $36,000. Caitong International Asset Management Co. Ltd purchased a new stake in Smith & Nephew SNATS in the 3rd quarter worth approximately $41,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC purchased a new position in shares of Smith & Nephew SNATS during the 4th quarter valued at $43,000. Hedge funds and other institutional investors own 25.64% of the company’s stock.

Wall Street Analyst Weigh In

SNN has been the subject of several research analyst reports. Weiss Ratings lowered Smith & Nephew SNATS from a “hold (c+)” rating to a “hold (c)” rating in a research note on Thursday, June 11th. The Goldman Sachs Group reaffirmed a “buy” rating on shares of Smith & Nephew SNATS in a report on Monday, May 25th. Wall Street Zen raised shares of Smith & Nephew SNATS from a “buy” rating to a “strong-buy” rating in a research note on Saturday, July 4th. Sanford C. Bernstein set a $31.85 price target on shares of Smith & Nephew SNATS in a report on Monday, May 11th. Finally, Kepler Capital Markets lowered Smith & Nephew SNATS from a “buy” rating to a “hold” rating in a research note on Thursday, June 4th. One research analyst has rated the stock with a Buy rating and five have given a Hold rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $30.93.

Smith & Nephew SNATS Stock Performance

Shares of Smith & Nephew SNATS stock opened at $31.08 on Tuesday. The company has a quick ratio of 1.25, a current ratio of 2.57 and a debt-to-equity ratio of 0.60. Smith & Nephew SNATS, Inc. has a 52-week low of $28.56 and a 52-week high of $38.79. The company has a fifty day moving average of $30.21 and a 200-day moving average of $32.42.

About Smith & Nephew SNATS

Smith & Nephew plc is a global medical technology company specializing in the design, development and manufacture of advanced surgical devices, orthopaedic reconstruction implants, trauma and extremities products, sports medicine solutions and wound care therapies. Founded in 1856 in Hull, United Kingdom, the company has grown through both organic innovation and strategic acquisitions to offer a broad portfolio that addresses patient needs across joint replacement, minimally invasive surgery and wound healing.

In its orthopaedics business, Smith & Nephew provides hip and knee replacement systems, modular joint revision implants and biologic solutions for bone repair.